Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Allergy drug and supplement face off in battle against cancer treatment bone pain

NCT ID NCT07300735

Symptom relief Sponsor: Alexandria University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two oral medications—diosmin-hesperidin (a flavonoid supplement) and loratadine (an allergy drug)—to prevent bone pain caused by G-CSF, a drug that boosts white blood cells in blood cancer patients. Researchers will compare each drug alone and in combination against a control in 88 adults. The goal is to find a safe, effective way to ease this common side effect.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Diosmin-Hesperidin and Loratadine
What this could lead to
If it works, this could point toward a simple, low-cost way to prevent a common side effect of cancer treatment.
What could go wrong
This is a small, early-stage study. The drugs may not reduce pain better than existing options, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 88 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults 18 to 65 years old * Receiving a G-CSF for one of the following indications: Treatment of neutropenia along with treatment for leukemia or lymphoma Neutropenia prevention following autologous hematopoietic cell transplant * Patients with or without bone pain associated with G-CSF administration. * Willingness to provide informed consent to participate in the study. Exclusion Criteria: * Patients with solid tumors. * Pregnant or breastfeeding women. * Patients with known allergies or hypersensitivity to Loratadine, Diosmin- Hespiridin or Filgrastim. * Patients with pre-existing bone disorders or receiving bone modifying agents * Chronic use of antihistamines, Diosmin-Hespiridin, NSAIDs, corticosteroids, or immunosuppressants. * Receiving medications with drug interaction grade X with Loratadine, Diosmin-Hespiridin or Filgrastim * Patients who are unable to understand or provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm neutropenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bone pain Hematologic malignancy Neutropenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Alexandria University Hospitals

    RECRUITING

    Alexandria, 21532, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.